Chengdu Kanghong Pharmaceuticals Group Co Ltd Asset Resilience Ratio
Chengdu Kanghong Pharmaceuticals Group Co Ltd asset resilience ratio. Chengdu Kanghong Pharmaceuticals Group Co Ltd (002773) has an Asset Resilience Ratio of 29.37% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of Chengdu Kanghong Pharmaceuticals Group C to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Chengdu Kanghong Pharmaceuticals Group Co Ltd (2015–2022)
Asset resilience ratio of Chengdu Kanghong Pharmaceuticals Group Co Ltd from 2015 to 2022. This chart shows how Chengdu Kanghong Pharmaceuticals Group Co Ltd's Asset Resilience Ratio has changed over time. Read 002773 total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Chengdu Kanghong Pharmaceuticals Group Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 002773 current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥2.92 Billion | 29.37% |
| Total Liquid Assets | CN¥2.92 Billion | 29.37% |
Asset Resilience Insights
- Very High Liquidity: Chengdu Kanghong Pharmaceuticals Group Co Ltd maintains exceptional liquid asset reserves at 29.37% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Chengdu Kanghong Pharmaceuticals Group Co Ltd Industry Peers by Asset Resilience Ratio
Compare Chengdu Kanghong Pharmaceuticals Group Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Sandoz Group AG
SW:SDZ |
Drug Manufacturers - Specialty & Generic | 7.89% |
|
H Lundbeck A/S
CO:HLUN-B |
Drug Manufacturers - Specialty & Generic | -0.56% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Viyash Scientific Limited
NSE:SEQUENT |
Drug Manufacturers - Specialty & Generic | 0.08% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
Chengdu Kanghong Pharmaceuticals Group Co Ltd Asset Resilience Ratio by Year (2015–2022)
Chengdu Kanghong Pharmaceuticals Group Co Ltd asset resilience ratio by year from 2015 to 2022. The table below shows the annual Asset Resilience Ratio data for Chengdu Kanghong Pharmaceuticals Group Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 1.30% | CN¥100.00 Million ≈ $14.63 Million |
CN¥7.72 Billion ≈ $1.13 Billion |
-1.58pp |
| 2021-12-31 | 2.88% | CN¥200.00 Million ≈ $29.27 Million |
CN¥6.96 Billion ≈ $1.02 Billion |
-1.21pp |
| 2018-12-31 | 4.08% | CN¥212.00 Million ≈ $31.02 Million |
CN¥5.19 Billion ≈ $760.17 Million |
-2.84pp |
| 2016-12-31 | 6.92% | CN¥260.00 Million ≈ $38.05 Million |
CN¥3.76 Billion ≈ $549.94 Million |
-0.32pp |
| 2015-12-31 | 7.24% | CN¥210.00 Million ≈ $30.73 Million |
CN¥2.90 Billion ≈ $424.54 Million |
-- |
About Chengdu Kanghong Pharmaceuticals Group Co Ltd
Chengdu Kanghong Pharmaceutical Group Co., Ltd engages in the research, development, manufacture, and sale of pharmaceuticals and medical devices in China. It develops medicines for ophthalmic, neuropsychiatric, and others. The company was founded in 1996 and is headquartered in Chengdu, China.